Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NY-ESO-1 TCR Therapy + Ipilimumab in Advanced Cancer
NCT02070406Phase 1Terminated
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Jul 2014
- Primary completion
- Dec 2018
- Modality
- Gene Editing, Gene Silencing, TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mipetresgene autoleucel in solid tumor, sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoints: Incidence of toxicity up to 5 years and Maximum tolerable dose at 60 days. Started Jul 2014; status: terminated.
02
Drugs
mipetresgene autoleucel
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02070406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02070406.